CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Clinical trials for CLINICAL STAGE IVA GASTRIC CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new CLINICAL STAGE IVA GASTRIC CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for CLINICAL STAGE IVA GASTRIC CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy aims to boost stomach cancer treatment before surgery
Disease control OngoingThis study tests whether combining two immunotherapy drugs (nivolumab and ipilimumab) with chemotherapy and radiation before surgery can safely treat stomach cancer. About 32 adults with resectable gastric or gastroesophageal junction cancer will receive this combination. The goa…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 10:45 UTC
-
New way to deliver chemotherapy shows promise for stomach cancer patients
Disease control OngoingThis early-phase study tests the safety and best dose of the chemotherapy drug paclitaxel when given directly into the abdomen for people with advanced stomach or gastroesophageal cancer that has spread to the lining of the abdomen. About 27 participants will receive the drug thr…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 10:40 UTC
-
Radiation boost may extend life for limited-spread stomach and esophageal cancers
Disease control OngoingThis study tests whether adding radiation therapy to standard chemotherapy helps people with HER2 negative esophageal or stomach cancer that has spread to only a few spots in the body. About 314 participants will receive either chemotherapy alone or chemotherapy plus radiation. T…
Matched conditions: CLINICAL STAGE IVA GASTRIC CANCER AJCC V8
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated May 14, 2026 12:06 UTC